Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Metagenomi Therapeutics (MGX) Non-cash Items (2023 - 2025)

Metagenomi (MGX) has disclosed Non-cash Items for 3 consecutive years, with $265000.0 as the latest value for Q4 2025.

  • Quarterly Non-cash Items fell 62.94% to $265000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $265000.0 through Dec 2025, down 62.94% year-over-year, with the annual reading at $265000.0 for FY2025, 62.94% down from the prior year.
  • Non-cash Items for Q4 2025 was $265000.0 at Metagenomi, down from $1.1 million in the prior quarter.
  • The five-year high for Non-cash Items was $111.0 million in Q4 2023, with the low at $3246.0 in Q2 2024.
  • Average Non-cash Items over 3 years is $14.3 million, with a median of $490000.0 recorded in 2024.
  • The sharpest move saw Non-cash Items plummeted 99.36% in 2024, then soared 27335.4% in 2025.
  • Over 3 years, Non-cash Items stood at $111.0 million in 2023, then tumbled by 99.36% to $715000.0 in 2024, then tumbled by 62.94% to $265000.0 in 2025.
  • According to Business Quant data, Non-cash Items over the past three periods came in at $265000.0, $1.1 million, and $890553.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.